Rallybio Corporation — Quarterly Cash Flow (NASDAQ:RLYB) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Total assets 79.01 M68.11 M57.98 M51 M67.66 M Total liabilities 8.19 M6.45 M3.91 M5.04 M4.63 M Total equity 70.82 M61.65 M54.07 M45.96 M63.03 M Total liabilities & shareholders' equities 79.01 M68.11 M57.98 M51 M67.66 M Total debt ————— Net debt —————

뉴스

랠리바이오 CFO, 3,992달러 상당 주식 매도

Lieber, Rallybio CFO, sells $3992 in shares

Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor

Rallybio announces one-for-eight reverse stock split effective Feb 6

Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested - TipRanks.com

랠리바이오, 2월 6일 1:8 역주식 분할 시행

Rallybio to implement 1-for-8 reverse stock split effective February 6

Rallybio completes first cohort dosing in RLYB116 C5 inhibitor study

Here's Why Shares in Recursion Pharmaceuticals Surged Today

Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio

Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Rallybio (NASDAQ:RLYB), Recursion Pharmaceuticals (NASDAQ:RXRX)

Rallybio sells HPP treatment program to Recursion for up to $25 million